Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Cadila Healthcare — Investor Presentation (March 2009)
19 slides from Zydus Lifesciences's investor presentation, March 2009
Slide 1: Cadila Healthcare Ltd Investor Presentation
Cadila Healthcare Ltd Investor Presentation March 2009 1
Slide 2: Our Vision
OUR VISION Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010; we shall achieve sales of over $3 bn by 2015 and be a research-based pharmaceutical company by 2020. 2
Slide 3: Zydus Cadila - Snapshot
ZYDUS CADILA - SNAPSHOT Ranked 5th in Indian formulations market. (Source : ORG IMS MAT Jan-09). Presence in developed generics markets (US, Europe, Japan) and emerging markets (Brazil, South Africa, CIS, Taiwan, Philippines and select other markets in Asia Pac and Africa region). Formulations e
Slide 4: State of the Art Facilities and Infrastructure
STATE OF THE ART FACILITIES AND INFRASTRUCTURE Formulations – five manufacturing plants Moraiya (Gujarat) - Largest integrated facility in Asia Baddi (Himachal Pradesh) – for domestic and regulated markets Sikkim – for domestic market Goa – for semi regulated markets Brazil – for caterin
Slide 5: Core Business Areas and Revenue Break-up (FY 07-08)
CORE BUSINESS AREAS AND REVENUE BREAK-UP (FY 07-08) Revenue break-up by segment Revenue break-up by region 5
Slide 6: Financial Highlights
FINANCIAL HIGHLIGHTS Operating Income ($ Mio) EBIDTA ($ Mio) ▲ 27% ▲ 31% 517 102 ▲ 23% ▲ 21% 406 78 330 65 FY 05-06 FY 06-07 FY 07-08 FY 05-06 FY 06-07 FY 07-08 Operating Net Profit ($ Mio) Operating EPS ($) ▲ 23% ▲ 23% 56 0.45 ▲ 24% ▲ 24% 46 0.36 37 0.29 FY 05-06 FY 06-07 FY 07-08 FY 05-06 FY 06-07
Slide 7: India Formulations – Shift of Focus
INDIA FORMULATIONS – SHIFT OF FOCUS Portfolio shift from acute to life style and chronic segments 2000-01 2007-08 7
Slide 8: Achievements in Indian Market
ACHIEVEMENTS IN INDIAN MARKET • Zydus Cadila ranks 5th with $ ~275 Mio. sales. (Source: ORG IMS MAT Jan-09) • Leading positions in the key therapeutic segments – Cardiovascular, Gastrointestinal, Female Healthcare and Respiratory (participated market segments, as per ORG IMS MAT Jan-09) • 16 Zydus b
Slide 9: International Formulations - Two Fold Focus
INTERNATIONAL FORMULATIONS - TWO FOLD FOCUS Developed generics markets Emerging markets • US - the largest generic market • Brazil – Nikkho (Branded), Zydus Brazil (Generics) • Zydus Pharmaceuticals USA Inc. • Asia Pacific- Sri Lanka, Myanmar, • Europe - Zydus France SAS Taiwan, Philippines • Labora
Slide 10: US – Marketing Plan and Achievements So Far
US – MARKETING PLAN AND ACHIEVEMENTS SO FAR World’s largest generics market Robust regulatory pipeline at ~ $ 35 bn, growing at 10-12% (Source : IGPA) Started operations in 2005 DMF Filings 71 Over half of the products use own API. Plan to file 12-15 ANDAs p.a. ANDA 80 filings Launched 22
Slide 11: Europe – Key Initiatives So Far
EUROPE – KEY INITIATIVES SO FAR Focus on Generics Product Launches New Markets Eur 2 bn market, Launched >100 Entered Spanish growing at ~11% (IMS) generic presentations market (5th largest in in France Europe) by acquiring Over 2% share in Plan to launch of 12- Laboratories Combix partici
Slide 12: Brazil – Key Initiatives
BRAZIL – KEY INITIATIVES $ 10 bn pharmaceutical market, growing at ~12% (Source : IMS) Entered generics market in 2005-06 thru 100% subsidiary, Zydus Healthcare Brazil Ltda Filed dossiers for 40 products so far, of which 18 have been approved and all have been launched Acquired of Nikkho do
Slide 13: Japan and Other Emerging Global Markets
JAPAN AND OTHER EMERGING GLOBAL MARKETS Acquired Nippon Universal Pharma. Ltd. in 2007-08 to gain entry in generics market of Japan, valued at ~$3 bn, growing at ~12% (Source : IGPA). Plan to introduce new products in Japan through in-licensing route as well product registrations from India. P
Slide 14: Consumer Healthcare – Building Strong Brands
CONSUMER HEALTHCARE – BUILDING STRONG BRANDS Presence in low calorie sweetener and skincare products business in India since more than 15 years. Sugar Free group - the healthier alternative to sugar Market leader in India with market share of >75% (Source : AC Nielsen). Growing at CAGR of ov
Slide 15: Contract Manufacturing - Exciting Prospects
CONTRACT MANUFACTURING - EXCITING PROSPECTS Zydus Nycomed JV – most successful contract manufacturing JV in India State of the art API mfg. plant for Pantoprazole intermediates Plan to expand scope of the JV, with more APIs to be sources by Nycomed from this JV over next 2-3 years Zydus Hosp
Slide 16: Research Focus
RESEARCH FOCUS Scientific Talent Pool ~ 800 Zydus Research Centre (ZRC) Located in Ahmedabad NME & Drug Discovery Focused on NME Research & 325 NDDS Generics / Developmental 325 Pharmaceutical Technology API & Others Centre (PTC) 150 2 centers – one located in Ahmedabad, another in Mumbai
Slide 17: Zydus Research Center - Investing for the Future
ZYDUS RESEARCH CENTER - INVESTING FOR THE FUTURE • NME Research, Biologicals (Biogenerics) & NDDS. • Therapeutic Area: Dyslipidemia, Diabetes, Obesity, Inflammation. • Infrastructure for target identification to pre-clinical research / early clinical development. • Multiple candidates under preclini
Slide 18: Highlights from Latest Financial Results
HIGHLIGHTS FROM LATEST FINANCIAL RESULTS $ Mio. Consolidated Apr-Dec Apr-Dec Growth 08 07 y-y% Domestic Sales (Net) 273 237 14.8% Exports Sales 207 145 43.4% Total Net Sales 480 382 25.6% Total Operating Income 490 391 25.1% PBIDT 101 77 31.8% PBIDT % to Total Income Net Operating Profit # 60 44 38.
Slide 19: Thank You.
Thank You. No part of this presentation may be reproduced, quoted or circulated without prior written approval from Cadila Healthcare Ltd.. This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actua
Cadila Healthcare — Investor Presentation (March 2009) on 6ix